iXCells Biotechnologies Announces Strategic Initiatives to Drive Continued Growth

Organizational restructure and key investments address increasing market demand

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies (the “Company”), a provider of induced pluripotent stem cells (iPSCs), differentiation services, primary cells, media and reagents for drug discovery and development, today announced key growth initiatives.

The Company is implementing a cloud-based ERP solution powered by Oracle NetSuite^® that will integrate workflows and create operational efficiencies. “Our rapid growth in recent years has hastened the need for a new solution capable of handling increasing market demand for our products and services while improving the order fulfillment experience for our valued customers," said Dr. Nianwei Lin, Co-Founder and President of iXCells Biotechnologies. “We’re expecting to complete the integration process with a go-live date next year.”

iXCells Biotechnologies has been restructuring its business and expanding teams with plans to hire additional scientists, marketing, and business development staff. Moreover, the Company has engaged the services of a corporate development advisor, Wayne Vaz, to help formulate and execute growth initiatives. “Having previously served with leading organizations in the annotated biomaterials space, Wayne’s background, including engineered and primary cells for drug discovery, bioproduction, and cell therapy applications, will be extremely helpful for enhancing our commercial plans and how we continue to deliver value for our customers,” said Dr. Lin.

Dr. Lynn Zhang, CEO/Chair of the Board, commented, “Investing in these key resources and talents at this stage in our Company’s development is vital for adding new capabilities, positioning the Company for future growth and scalability, and continuing to make iXCells Biotechnologies a highly valued partner.”

iXCells Biotechnologies is a highly sought-after partner by life science researchers looking for innovative solutions in disease relevant cell models needed for drug discovery workflows.

About iXCells Biotechnologies

Founded in 2014 and based in San Diego, CA, iXCells Biotechnologies is an innovative cell biology and cell technology company that provides preclinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate the pace of drug discovery. iXCells offers customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and drug screening. To learn more about this innovative leader within the preclinical iPSC sector, visit www.ixcellsbiotech.com.

Follow iXCells Biotechnologies on Twitter, Facebook, and on LinkedIn